Corporate Goals and Objectives

Immediate Objectives
- Optimize the pharmacodynamics and pharmacokinetics of the peptide
- Determine a dose-response relationship of DT-109, Byetta, and Onglyza (dipeptidyl peptidase-4 (DPP-4) inhibitor), in a mouse diabetes model, to compare efficacy
- Determine if DT-109 can differentiate itself from the other compounds in a model of metabolic syndrome (ZSF-1 rats)
Intermediate Goals
- Complete preclinical development
- Identify a partner or investor consortium to fund clinical trials for DT-109
Long-term Goal
- Move DT-109 to global markets by leveraging co-development partnerships with large pharmaceutical companies